{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:02:19Z","timestamp":1790118139418,"version":"4.0.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T00:00:00Z","timestamp":1294617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Imatinib mesylate, a tyrosine kinase inhibitor, exhibits a weak competitive inhibition on paracetamol (acetaminophen) <jats:italic>O<\/jats:italic>\u2010glucuronidation with an inhibition constant (<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>) value of 59\u2003\u00b5<jats:sc>m<\/jats:sc>. However, the clinical significance of the inhibition has not been evaluated. The pharmacokinetics of imatinib have been studied in white patients with chronic myelogenous leukaemia (CML), but not in Korean patients with CML.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Imatinib (400\u2003mg once daily) had no clinically relevant effect on the plasma exposure and the pharmacokinetics of paracetamol (1000\u2003mg once daily) in patients with CML.<\/jats:p><jats:p>\u2022\u2003The pharmacokinetic profile of imatinib in Korean patients with CML was similar to that in whites.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> The major objective of the present study was to investigate the effect of imatinib on the pharmacokinetics of paracetamol in patients with chronic myelogenous leukaemia (CML).<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> Patients (<jats:italic>n<\/jats:italic>= 12) received a single oral dose of acetaminophen 1000\u2003mg on day 1 (control). On days 2\u20138, imatinib 400\u2003mg was administered daily. On day 8 (treatment), another 1000\u2003mg dose of paracetamol was administered 1\u2003h after the morning dose of imatinib 400\u2003mg. Blood and urine samples were collected for bioanalytical analyses.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> The area under the plasma concentration\u2013time curve (AUC) for paracetamol, paracetamol glucuronide and paracetamol sulphate under control conditions was similar to that after treatment with imatinib; the 90% confidence interval of the log AUC ratio was within 0.8 to 1.25. Urinary excretion of paracetamol, paracetamol glucuronide and paracetamol sulphate was also unaffected by imatinib. The pharmacokinetics of paracetamol and imatinib in Korean patients with CML were similar to previous pharmacokinetic results in white patients with CML. Co\u2010administration of a single dose of paracetamol and multiple doses of imatinib was well tolerated and safety profiles were similar to those of either drug alone.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> The pharmacokinetics of paracetamol and its major metabolites in the presence of imatinib were similar to those of the control conditions and the combination was well tolerated. These findings suggest that imatinib can be safely administered with paracetamol without dose adjustment of either drug.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03810.x","type":"journal-article","created":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T01:19:27Z","timestamp":1285636767000},"page":"199-206","source":"Crossref","is-referenced-by-count":20,"title":["Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia"],"prefix":"10.1111","volume":"71","author":[{"given":"Dong\u2010Wook","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Demirhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Schran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200055972"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544090-00001"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0832-z"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0722-9"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.16.1508.50958"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.06.007"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2185"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601152"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03150.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/20014091111677"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01193.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00808.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90295-8"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(89)90278-6"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974164676"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(01)00611-0"},{"key":"e_1_2_7_20_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products \u2013 General Considerations. March 2003. Available athttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070124.pdf(last accessed 4 August 2010)."},{"key":"e_1_2_7_21_2","unstructured":"Committee for Proprietary Medicinal Products (CPMP).Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 26 July 2001. Available athttp:\/\/faculty.ksu.edu.sa\/64448\/Documents\/EMEA%20Guideline%20BE.pdf(last accessed 4 August 2010)."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004283"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_7_24_2","first-page":"229","article-title":"Pharmacokinetics and bioavailability of tablet PVP\u2010acetaminophen in healthy volunteers after a single oral dose study","volume":"11","author":"Zhao Y","year":"1995","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00712-8"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600800911"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03988.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315313"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb00503.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609245"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059791"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03810.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03810.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:56:51Z","timestamp":1697443011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03810.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,10]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03810.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03810.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,10]]}}}